# Czech Medtech Kardi Ai Raises EUR 5.3M Series A at EUR 23M Valuation to Predict Heart Rhythm Risk Before Arrhythmia Strikes
> Czech medtech Kardi Ai raises EUR 5.3M Series A led by Callisto Health to expand wearable ECG heart monitoring and build predictive arrhythmia models.
- **Author:** Prashant Jagtap
- **Published:** 2026-11-11
- **Updated:** 2026-11-11
- **Category:** Startups
- **Editorial type:** news
- **Topics:** series-a, medtech, czech-startups
- **Canonical URL:** https://www.todaysstartupnews.com/startups/kardi-ai-raises-5-3m-series-a-callisto-health-predictive-heart-monitoring
## Key takeaways
- Czech medtech startup Kardi Ai has raised EUR 5.3 million in a Series A round led by German healthtech fund Callisto Health, valuing the company at EUR 23 million
- Seed Starter, the venture programme of Česká spořitelna and Slovenská sporiteľňa, joined alongside BrightCap Ventures, Purple Ventures, DEPO Ventures and Garage Angels
- The platform pairs a fitness chest strap with an ECG sensor, a mobile app and AI analysis to monitor heart rhythm during daily life
- The company works with more than 70 hospitals and over 20 corporate partners in the Czech Republic, and more than 6,000 people use its technology
- Funds will support launches in Germany, India, the UAE and Singapore and the development of models that estimate arrhythmia risk before it occurs
Kardi Ai, a Czech medtech startup that develops long-term heart rhythm monitoring technology, has raised EUR 5.3 million in a Series A round led by German healthtech fund Callisto Health. The company announced the round on November 11, 2026, and says it is the largest round a Czech medtech startup has raised to date. The round values Kardi Ai at EUR 23 million.

Česká spořitelna and Slovenská sporiteľňa joined through their corporate venture programmes, both operating under the Seed Starter name. Earlier backers BrightCap Ventures, Purple Ventures, DEPO Ventures and Garage Angels also took part. For Slovenská sporiteľňa's Seed Starter, Kardi Ai is the first healthtech investment.

Kardi Ai's product is a fitness chest strap with a built-in ECG sensor that connects to a mobile app, where AI analyses the recordings. People wear the strap during their normal day, see the results themselves and can pass them to their doctor when needed. Heart rhythm disorders such as arrhythmias often come and go, so a short check-up at a clinic can miss them, and longer monitoring is meant to capture what a brief test does not. The system does not make a diagnosis. The company positions it as a source of data that helps physicians decide on further care.

The startup was founded in Olomouc in 2022 by cardiologist Prof. Tomáš Skála, entrepreneur Stephen Burke, technologist Pavel Digaňa and product designer David Skála. Vlastimil Hrabal joined the founding team later as chief executive.

In the Czech Republic, Kardi Ai works with more than 70 hospitals and over 20 corporate and employee-benefit partners, and more than 6,000 people use its technology. It has been offered to staff at Česká spořitelna as an employee benefit since 2024. In May 2026 the company became the first Czech startup to win Best HealthTech Startup at the global final of the Global Startup Awards.

The company entered Slovakia a few months ago, mostly through a local distributor. It now works with more than 20 physicians there, most of them cardiologists, including at Bory Hospital and the Corfil cardiology clinic. Besides hospitals and clinics, Kardi Ai sells through its own e-shop, Alza and the online pharmacy Moja Lekáreň. It already operates in Czechia, Slovakia, Poland, Romania and Bulgaria.

The new funding is directed at two goals. The first is geographic expansion in Europe and Asia. Germany is the main European target, where Kardi Ai has completed pilot projects and is preparing to launch. In July 2026, the company received an MD-15 import licence from India's regulator CDSCO, covering both its hardware and software. The Indian launch will start in Hyderabad, where it is in talks with healthcare partners, and operations there are planned to begin in the last quarter of 2026. In the United Arab Emirates, Kardi Ai holds a Medical Device Registration Certificate from the Ministry of Health and Prevention. It is also finishing medical device approval in Singapore, which it plans to use as an entry point to Southeast Asia, with the Philippines, Indonesia and Vietnam among the next markets on its list.

The second goal is predictive technology. Kardi Ai intends to develop models that analyse data from multiple ECG measurements to estimate the risk of cardiac arrhythmias before they occur. Hrabal said the company is gradually moving beyond detecting heart rhythm disorders towards identifying an increased risk before an arrhythmia appears, and that nearly two billion people live in the markets where it already operates or is preparing to launch. He added that the new capital will allow the company to validate the technology at global scale and across patient demographics, and to pursue its ambition of becoming a leading provider of long-term ECG monitoring in those markets.

Dr Stefan Eckhardt of Callisto Health said the team has built a certified medical product that is easy to use and is already used in real-world settings in Central and Eastern Europe. Tomáš Milota, chief executive of Seed Starter at Česká spořitelna, said the bank is investing in a solution it has validated internally, at a time when the company has achieved MDR certification and is preparing for its next growth phase.